Every time a pharmaceutical company submits a new drug to the US Food and Drug Administration, a clock starts. That clock ends on the PDUFA date. For anyone working in life sciences, whether in regulatory affairs, clinical research, investment, or commercial planning, understanding what a PDUFA date is, how it is set, and what it means in practice is foundational knowledge.
What PDUFA Stands For
PDUFA is the Prescription Drug User Fee Act. The act was created by Congress in 1992 and authorises the FDA to collect user fees from companies that submit certain human drug applications for review. The legislation was a direct response to a growing crisis in the approval process. Drug applications used to take years to be reviewed because the FDA did not have enough staff and resources to work quickly. Such long delays slowed access to new therapies for patients and left companies waiting for a decision, with no end in sight.
Since its enactment, user fees have helped cut New Drug Application (NDA) and Biologics Licensing Application (BLA) priority and standard review times in half, helping get new medicines to patients faster. Before PDUFA, average approval decision times were between 21 and 29 months. The time is now half that, with 10 months being the average.
PDUFA must be reauthorised every five years and was renewed in 1997, 2002, 2007, 2012, 2017, and most recently in 2022 as PDUFA VII, which runs through September 2027. Planning for the next reauthorisation, PDUFA VIII, is already under way: the FDA held a public meeting on 14 July 2025 to discuss proposed recommendations for PDUFA’s reauthorisation for fiscal years 2028 through 2032.
What the PDUFA Date Actually Means
The PDUFA date refers to the deadline set by the FDA for reviewing an NDA or BLA and making a final decision on marketing approval. It is sometimes called the action date or the goal date.
The date is set once the FDA formally accepts an application for review. The typical review period is 10 months after the drug application has been accepted by the agency. For drugs that have received priority review, the review period is reduced to six months from the time of application acceptance.
It is worth being precise about what the PDUFA date represents. It is a commitment by the FDA to deliver a decision by that point. It is not a guarantee of approval, and decisions can, in some circumstances, come before the date if the review concludes early.
The Three Possible Outcomes
On or before the PDUFA date, the FDA will either approve the NDA, issue a complete response letter (CRL), or deny the NDA.
An approval letter means the product can be legally marketed in the United States. This is the outcome every drug sponsor works towards. Outright denial is rare. The more common alternative to approval is the CRL.
A CRL is issued when the application cannot be approved in its current state, typically due to safety, efficacy, or manufacturing concerns. Once the drug sponsor addresses deficiencies, the application may be resubmitted, and a new review timeline and PDUFA date will be provided.
Receiving a CRL does not mean the drug’s development is over. Many approved drugs received one or more CRLs before eventually reaching market. It does, however, add time and cost to the process, and the nature of the deficiencies cited will determine how quickly a sponsor can respond.
What Is a PDUFA Date in the Context of NDA and BLA Submissions
To understand the PDUFA date fully, it helps to understand the submissions it applies to. Prior to marketing, a manufacturer must submit an NDA or BLA to the FDA, demonstrating a drug or biologic’s safety and effectiveness. FDA scientific and regulatory personnel review the NDA or BLA and prepare written assessments across several categories, including medical, chemistry, statistical, pharmacology, clinical pharmacology and biopharmaceutics, risk assessment and risk mitigation, and patient labelling, before deciding whether or not to approve the drug or biologic.
An NDA applies to small molecule drugs. A BLA applies to biological products, including monoclonal antibodies and gene therapies. Both follow the same PDUFA framework. Since 2015, the FDA has approved an average of 47 new medications each year. In 2024, there were 50 new drugs, with 48% approved as first in class; additionally, 52% received orphan drug designation targeting rare diseases, and 66% used one or more expedited programmes.
Expedited Programmes and Their Effect on the PDUFA Timeline
The FDA offers several designations that can compress the review timeline or provide additional support during development. These are distinct from the PDUFA framework itself, but interact with it directly.
Priority review reduces the standard 10-month clock to six months. Priority review designations are granted to medications that provide treatment of disease states that previously did not have any available options or may offer major advances in treatment.
Breakthrough therapy designation goes further. It applies to a new drug product intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and for which preliminary clinical evidence indicates the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints. This designation includes all features of fast track, with more intensive FDA engagement during development.
Fast track designation focuses on facilitating development and expediting review for drugs intended to treat serious conditions with potential to address unmet medical needs. Accelerated approval allows drugs for serious conditions to be approved on the basis of a surrogate endpoint, with post-market confirmatory trials required.
In 2024, 66% of new drugs used one or more expedited programmes, including fast track designation, breakthrough therapy designation, priority review designation, and accelerated approval. The increasing use of these pathways reflects both the FDA’s intent to improve access for patients with serious conditions and the pharmaceutical industry’s growing sophistication in seeking them.
Advisory Committees and the Review Process
Alongside the PDUFA timeline, the FDA may convene an advisory committee, often called an AdCom, to provide independent expert input on a drug’s risk-benefit profile. Advisory committees do not make the final decision. That authority rests with the FDA. However, AdCom votes carry significant weight and are closely watched by sponsors, investors, and the clinical community.
Not all applications go before an advisory committee. The FDA typically convenes one when the data are particularly complex, when there are unresolved safety questions, or when the drug represents a novel mechanism of action with limited clinical precedent.
Why the PDUFA Date Matters Beyond Regulatory Affairs
For regulatory affairs teams, the PDUFA date structures the entire late-stage submission process. For commercial teams, it anchors launch planning. For investors, it is one of the most consequential catalysts in biotech and pharma. A PDUFA date is the culmination of years of research, significant investment, and regulatory scrutiny, and the FDA’s final decision deadline determines whether a drug becomes a market opportunity or a clinical setback.
Stock prices for smaller biotech companies can move sharply in the days surrounding a PDUFA date. For companies with a single pipeline asset, the outcome can determine the company’s near-term viability. For larger pharmaceutical companies, it shapes revenue forecasts and portfolio strategy.
Healthcare systems and hospital pharmacy teams have also begun building PDUFA tracking into operational planning, anticipating formulary reviews, reimbursement negotiations, and clinical pathway updates ahead of approval decisions.
Extensions and Changes to the PDUFA Date
The PDUFA date is a target, not a fixed deadline under all circumstances. The FDA can extend a review by three months if a sponsor submits a major amendment to the application during the review period. Extensions can also occur when the agency requests additional information from the sponsor.
Recent examples illustrate how this plays out. In May 2026, the FDA requested additional information during the review process for LEQEMBI IQLIK, classifying the response as a major amendment to the application and extending the PDUFA date by three months to August 24, 2026. Such extensions are communicated formally and typically accompanied by an explanation of the outstanding information required.
When a resubmission follows a CRL, a new PDUFA date is established. Once the drug sponsor addresses deficiencies, the application may be resubmitted, and a new review timeline and PDUFA date will be provided. The class of resubmission, whether Class 1 or Class 2, determines the length of the new review period, with Class 1 resubmissions reviewed within two months and Class 2 within six.
A Practical Summary
The PDUFA date is the FDA’s commitment to deliver a decision on a drug application within a defined timeframe. It emerged from a legislative framework designed to address chronic delays in the approval process, and its introduction has demonstrably accelerated the pathway from clinical evidence to patient access.
For life science professionals, tracking PDUFA dates, understanding the designations that shape them, and interpreting the outcomes they generate is central to regulatory strategy, commercial planning, and clinical care. The date itself is a marker, but the decisions made around it, from how an application is built to how a sponsor responds to a CRL, are where the real work happens.
